SOBR 10-Q Quarterly Report Sept. 30, 2013

SOBR SAFE, INC.

10-Ks and 10-Qs

10-Q	Quarter ended Sept. 30, 2025
10-Q	Quarter ended June 30, 2025
10-Q	Quarter ended March 31, 2025
10-K	Fiscal year ended Dec. 31, 2024
10-Q	Quarter ended Sept. 30, 2024
10-Q	Quarter ended June 30, 2024
10-Q	Quarter ended March 31, 2024
10-K	Fiscal year ended Dec. 31, 2023
10-Q	Quarter ended Sept. 30, 2023
10-Q	Quarter ended June 30, 2023
10-Q	Quarter ended March 31, 2023
10-K	Fiscal year ended Dec. 31, 2022
10-Q	Quarter ended Sept. 30, 2022
10-Q	Quarter ended June 30, 2022
10-Q	Quarter ended March 31, 2022
10-K	Fiscal year ended Dec. 31, 2021
10-Q	Quarter ended Sept. 30, 2021
10-Q	Quarter ended June 30, 2021
10-Q	Quarter ended March 31, 2021
10-K	Fiscal year ended Dec. 31, 2020
10-Q	Quarter ended Sept. 30, 2020
10-Q	Quarter ended June 30, 2020
10-Q	Quarter ended March 31, 2020
10-K	Fiscal year ended Dec. 31, 2019
10-Q	Quarter ended Sept. 30, 2019
10-Q	Quarter ended June 30, 2019
10-Q	Quarter ended March 31, 2019
10-K	Fiscal year ended Dec. 31, 2018
10-Q	Quarter ended Sept. 30, 2018
10-Q	Quarter ended June 30, 2018
10-Q	Quarter ended March 31, 2018
10-K	Fiscal year ended Dec. 31, 2017
10-Q	Quarter ended Sept. 30, 2017
10-Q	Quarter ended June 30, 2017
10-Q	Quarter ended March 31, 2017
10-K	Fiscal year ended Dec. 31, 2016
10-Q	Quarter ended Sept. 30, 2016
10-Q	Quarter ended June 30, 2016
10-Q	Quarter ended March 31, 2016
10-K	Fiscal year ended Dec. 31, 2015
10-Q	Quarter ended Sept. 30, 2015
10-Q	Quarter ended June 30, 2015
10-Q	Quarter ended March 31, 2015
10-K	Fiscal year ended Dec. 31, 2014
10-Q	Quarter ended Sept. 30, 2014
10-Q	Quarter ended June 30, 2014
10-Q	Quarter ended March 31, 2014
10-K	Fiscal year ended Dec. 31, 2013
10-Q	Quarter ended Sept. 30, 2013
10-Q	Quarter ended June 30, 2013
10-Q	Quarter ended March 31, 2013
10-K	Fiscal year ended Dec. 31, 2012
10-Q	Quarter ended Sept. 30, 2012
10-Q	Quarter ended June 30, 2012
10-Q	Quarter ended March 31, 2012
10-K	Fiscal year ended Dec. 31, 2011
10-Q	Quarter ended Sept. 30, 2011
10-Q	Quarter ended June 30, 2011
10-Q	Quarter ended March 31, 2011
10-K	Fiscal year ended Dec. 31, 2010
10-Q	Quarter ended Sept. 30, 2010
10-Q	Quarter ended June 30, 2010
10-Q	Quarter ended March 31, 2010
10-K	Fiscal year ended Dec. 31, 2009

PROXIES

DEF 14A	Filed on July 17, 2025
DEF 14A	Filed on June 23, 2025
DEF 14A	Filed on Dec. 9, 2024
DEF 14A	Filed on Nov. 15, 2024
DEF 14A	Filed on July 22, 2024
DEF 14A	Filed on June 24, 2024
DEF 14A	Filed on June 3, 2024
DEF 14A	Filed on May 13, 2024
DEF 14A	Filed on April 28, 2023
DEF 14A	Filed on Nov. 24, 2021

10-Q 1 imle_10q.htm FORM 10-Q imle_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2013

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________.

Commission file number: 000-53316

TRANSBIOTEC, INC.

(Exact name of registrant as specified in its charter)

Delaware		26-0731818
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

194 Marina Drive, Suite 202 Long Beach, CA		90803
(Address of principal executive offices)		(Zip Code)

(562) 280-0483

Registrant’s telephone number, including area code

(Former address, if changed since last report)

(Former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	o	Smaller reporting company	x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

Applicable only to issuers involved in bankruptcy proceedings during the preceding five years:

Indicate by check mark whether the registrant filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes o No o

Applicable only to corporate issuers:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of November 13, 2013, there were 34,146,712 shares of common stock, $0.00001 par value, issued and outstanding .

TRANSBIOTEC, INC.

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION

ITEM 1	Financial Statements	4

ITEM 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18

ITEM 3	Quantitative and Qualitative Disclosures About Market Risk	25

ITEM 4	Controls and Procedures	25

PART II – OTHER INFORMATION

ITEM 1	Legal Proceedings	26

ITEM 1A	Risk Factors	27

ITEM 2	Unregistered Sales of Equity Securities and Use of Proceeds	27

ITEM 3	Defaults Upon Senior Securities	27

ITEM 4	Mine Safety Disclosures	27

ITEM 5	Other Information	27

ITEM 6	Exhibits	28

PART I – FINANCIAL INFORMATION

This Quarterly Report includes forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements are based on management’s beliefs and assumptions, and on information currently available to management. Forward-looking statements include the information concerning our possible or assumed future results of operations set forth under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements also include statements in which words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “consider,” or similar expressions are used.

Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties, and assumptions. Our future results and shareholder values may differ materially from those expressed in these forward-looking statements. Readers are cautioned not to put undue reliance on any forward-looking statements.

ITEM 1

Financial Statements

The unaudited consolidated financial statements of registrant for the three and nine months ended September 30, 2013 and 2012 follow. The consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. All such adjustments are of a normal and recurring nature.

TransBiotec, Inc.

(A Development Stage Company)

CONSOLIDATED BALANCE SHEET

	Sept. 30, 2013
	(unaudited)			Dec. 31, 2012

ASSETS

Current assets
Cash	$	837		$	782
Total current assets		837			782

Fixed assets - net		1,425			1,496
Patents & Trademarks		1,000			-

Total Assets	$	3,262		$	2,278


LIABILITIES & STOCKHOLDERS' EQUITY

Current liabilities
Accounts payable	$	459,607		$	298,994
Accrued interest payable		156,348			159,355
Notes payable - current - related parties		703,516			390,915
Notes payable - current		480,398			225,136
Note discount		(29,164	)		(38,072	)
Notes payable - equity obligation payable		447,602			463,037
Stock subscription payable - current		26,000			26,000
Related party payables		360,424			351,310
Other payables		-			158,006
Total current liabilties		2,604,731			2,034,681

Notes payable - related parties		167,007			363,888

Total Liabilities		2,771,738			2,398,569

Stockholders' Equity
Common stock, $.00001 par value;
100,000,000 shares authorized;
34,146,712 and 30,315,554 shares
issued and outstanding at September 30, 2013		342			303
and December 31, 2012 respectively
Additional paid in capital		12,380,124			11,903,279
Deficit accumulated during the
development stage		(15,118,407	)		(14,274,244	)
Total Transbiotec, Inc. stockholders' equity		(2,737,941	)		(2,370,662	)
Noncontrolling interest		(30,535	)		(25,629	)

Total Stockholders' Equity		(2,768,476	)		(2,396,291	)

Total Liabilities and Stockholders' Equity	$	3,262		$	2,278

The accompanying notes are an integral part of the consolidated financial statements.

TransBiotec, Inc.

(A Development Stage Company)

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

													Period From
	For Three Months Ended						For Nine Months Ended						July 19, 2004
	September 30,						September 30,						(Inception) To
	2013			2012			2013			2012			Sept. 30, 2013

Revenues	$	-		$	-		$	-		$	-		$	-
		-			-			-			-			-

Operating expenses:
Amortization & depreciation		194			152			582			303			76,931
General and administrative		117,832			138,199			500,370			2,315,046			13,068,319
		118,026			138,351			500,952			2,315,349			13,145,250

Gain (loss) from operations		(118,026	)		(138,351	)		(500,952	)		(2,315,349	)		(13,145,250	)

Other income (expense):
Gain/(Loss) on fair value adjustment - derivatives		318,799			-			(70,498	)		-			(518,635	)
Stock option expense		(40,377	)		-			(121,330	)		-			(121,330	)
Gain on debt reversal		81,307			-			86,878			-			86,878
Gain on sale of fixed asset		-			-			-			4,790			4,790
Interest expense		(25,014	)		(20,704	)		(91,071	)		(69,384	)		(1,184,063	)
Interest expense - beneficial conversion feature		(19,501	)		(38,217	)		(152,993	)		(102,388	)		(335,057	)
		315,214			(58,921	)		(349,014	)		(166,982	)		(2,067,417	)

Income (loss) before provision for income taxes		197,188			(197,272	)		(849,966	)		(2,482,331	)		(15,212,667	)

Provision for income tax		-			-			-			-			-

Net income (loss)		197,188			(197,272	)		(849,966	)		(2,482,331	)		(15,212,667	)
Less: Net (income) loss attributable to
noncontrolling interest		618			2,686			5,803			7,860			94,260
Net income (loss) attributable
to TranBioTec, Inc.	$	197,806		$	(194,586	)	$	(844,163	)	$	(2,474,471	)	$	(15,118,407	)

Net income (loss) per share (TransBiotec, Inc.)
(Basic and fully diluted)	$	0.01		$	(0.01	)	$	(0.03	)	$	(0.09	)

Weighted average number of
common shares outstanding		33,431,576			28,250,526			32,005,187			27,384,853

The accompanying notes are an integral part of the consolidated financial statements.

TransBiotec, Inc.

(A Development Stage Company)

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

							Period From
	For Nine Months Ended						July 19, 2004
	September 30,						(Inception) To
	2013			2012			September 30, 2013

Cash Flows From Operating Activities:
Net income (loss)	$	(844,163	)	$	(2,474,471	)	$	(15,206,864	)

Adjustments to reconcile net loss to
net cash provided by (used for)
operating activities:
Amortization & depreciation		582			303			76,931
Compensatory equity issuances		77,433			1,898,957			8,742,749
Asset write offs		-			850			37,513
Accrued payables		276,650			89,941			2,526,079
Gain on sale of fixed asset		-			(4,790	)		(4,790	)
Gain on debt reversal		(86,878	)		-			(86,878	)
Fair value adjustments - equity obligation		70,498			-			518,635
Note pay. benefical conversion expense		152,993			140,821			538,621
Original issue discount - interest expense		12,501			-			74,002
Other		-			-			292
Net cash provided by (used for)
operating activities		(340,384	)		(348,389	)		(2,783,710	)

Cash Flows From Investing Activities:
Fixed asset purchases		(511	)		(970	)		(78,356	)
Fixed asset sales		-			4,790			1,250
Net cash provided by (used for)
investing activities		(511	)		3,820			(77,106	)

(Continued On Following Page)

The accompanying notes are an integral part of the consolidated financial statements.

TransBiotec, Inc.

(A Development Stage Company)

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Continued From Previous Page)

							Period From
	For Nine Months Ended						July 19, 2004
	September 30,						(Inception) To
	2013			2012			Sept. 30, 2013

Cash Flows From Financing Activities:
Notes & loans payable - borrowings		346,232			149,386			1,369,379
Notes & loans payable - payments		(52,000	)		-			(90,726	)
Repurchase of equity		-			-			(250,000	)
Stock subscription payable		-			-			10,000
Equity issuances		47,500			90,000			1,823,000
Net cash provided by (used for)
financing activities		341,732			239,386			2,861,653

Net Increase (Decrease) In Cash		837			(105,183	)		837

Cash At The Beginning Of The Period		-			108,019			-

Cash At The End Of The Period	$	837		$	2,836		$	837


Schedule Of Non-Cash Investing And Financing Activities

Compensatory equity issuances	$	77,433		$	1,898,957		$	8,795,251
Debt converted to capital	$	49,000		$	59,000		$	1,606,875
Note to stock subscription payable	$	-		$	-		$	16,000

Supplemental Disclosure

Cash paid for interest	$	-		$	6,375		$	14,394
Cash paid for income taxes	$	-		$	-		$	-

The accompanying notes are an integral part of the consolidated financial statements.

TransBiotec, Inc.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

TransBiotec, Inc. (“TransBiotec – DE”), formerly Imagine Media LTD., was incorporated August, 2007 in the State of Delaware. A corporation also named TransBiotec, Inc. (“TransBiotec – CA”) was formed in the state of California July 4, 2004. Effective September 19, 2011 TransBiotec - DE was acquired by TransBiotec - CA in a transaction classified as a reverse acquisition as the shareholders of TransBiotec - CA retained the majority of the outstanding common stock of TransBiotec - DE after the share exchange. The financial statements represent the activity of TransBiotec - CA from July 4 2004 forward, and the consolidated activity of TransBiotec - DE and TransBiotec - CA from September 19, 2011 forward. TransBiotec - DE and TransBiotec - CA are hereinafter referred to collectively as the "Company". The Company has developed and plans to market and sell a non-invasive alcohol sensing system which includes an ignition interlock. The Company is currently considered to be in the development stage, and has not generated revenues from its activities.

Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and disclosures required by generally accepted accounting principles for complete financial statements. All adjustments which are, in the opinion of management, necessary for a fair presentation of the results of operations for the interim periods have been made and are of a recurring nature unless otherwise disclosed herein. The results of operations for such interim periods are not necessarily indicative of operations for a full year.

Principles of consolidation

The accompanying consolidated financial statements include the amounts of the Company and its majority owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

TransBiotec, Inc.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont’d)

Cash and cash equivalents

The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents.

Accounts receivable

The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. At September 30, 2013, and September 30, 2012 the Company had no balance in accounts receivable or the allowance for doubtful accounts.

Property and equipment

Property and equipment are recorded at cost and depreciated under straight line methods over each item's estimated useful life.

Revenue recognition

Revenue is recognized on an accrual basis as earned under contract terms. The Company has had no revenues to date

Advertising costs

Advertising costs are expensed as incurred. The Company recorded no material advertising costs during the nine months ended September 30, 2013 or 2012.

Income tax

The Company accounts for income taxes pursuant to ASC 740. Under ASC 740 deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

TransBiotec, Inc.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont’d)

Net income (loss) per share

The net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of shares of common outstanding. Warrants, stock options, and common stock issuable upon the conversion of the Company's preferred stock (if any), are not included in the computation if the effect would be anti-dilutive and would increase the earnings or decrease loss per share.

Financial Instruments

The carrying value of the Company’s financial instruments, as reported in the accompanying balance sheets, approximates fair value.

Long-Lived Assets

In accordance with ASC 350, the Company regularly reviews the carrying value of intangible and other long-lived assets for the existence of facts or circumstances, both internally and externally, that may suggest impairment. If impairment testing indicates a lack of recoverability, an impairment loss is recognized by the Company if the carrying amount of a long-lived asset exceeds its fair value.

Products and services, geographic areas and major customers

The Company is currently in the developmental stage and has no revenue.

Stock based compensation

The Company accounts for employee and non-employee stock awards under ASC 718, whereby equity instruments issued to employees for services are recorded based on the fair value of the instrument issued and those issued to non-employees are recorded based on the fair value of the consideration received or the fair value of the equity instrument, whichever is more reliably measurable.

TransBiotec, Inc.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Minority interest (Noncontrolling interest)

A subsidiary of the Company has minority members, representing ownership interests of 1.38% at March 31, 2013. The Company accounts for these minority, or noncontrolling interests pursuant to ASC 810-10-65 whereby gains and losses in a subsidiary with a noncontrolling interest are allocated to the noncontrolling interest based on the ownership percentage of the noncontrolling interest, even if that allocation results in a deficit noncontrolling interest balance.

NOTE 2. RELATED PARTY TRANSACTIONS

During the six months ended September 30, 2013 and September 30, 2012, the Company had payables due to officers, shareholders and former management for accrued compensation and services of $172,765 and $79,199 respectively.

During the year ended December 31, 2011 related party shareholders converted $829,164 in note principal and interest and $135,000 in compensation into 2,408,977 common shares.

NOTE 3. FIXED ASSETS

Fixed asset values recorded at cost are as follows:

							(unaudited)
	December 31,			December 31,			September 30,
	2011			2012			2013

Automobile	$	33,383		$	-		$	-
Office and Lab Equipment		31,896			31,616			32,127
Furniture & fixtures		11,596			11,556			11,556
		76,875			43,172			43,683

Less accumulated depreciation		(75,743	)		(41,676	)		(42,258	)

Total	$	1,132		$	1,496		$	1,425

Depreciation expense for the nine months ended Septemer 30, 2013 and September 30, 2012 was $582 and $303, respectively.

TransBiotec, Inc.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4. NOTES PAYABLE

	December 31, 2011		December 31, 2012		(Unaudited) Sept. 30, 2013
Note payable to related party, unsecured, due 8/3/2012, interest rate 0%	$	1,950	$	1,950	$	1,950

Notes payable to related parties, unsecured, due 12/31/2012, interest rate 0%	$	11,810	$	11,810	$	11,810

Note payable to non-related party, unsecured, due 09/15/2012, convertible at holder’s option at $2.50 per TBT - CA share.	$	16,000		-		-

Note payable to non-related party, unsecured, due 2/8/12, quarterly interest due, convertible at holder’s option at $0.3235688 per TBT - DE share, interest rate 30%	$	10,000	$	10,000	$	10,000

Note payable to non-related party, unsecured, due 2/8/12, quarterly interest due, convertible at holder’s option at $0.3235688 per TBT - DE share, interest rate 30%	$	25,000	$	25,000	$	25,000

Note payable to non-related party, unsecured, due 2/17/12, quarterly interest due, convertible at holder’s option at $0.3235688 per TBT - DE share, interest rate 30%	$	25,000	$	25,000	$	25,000

Note payable to non-related party, unsecured, due 2/18/12, quarterly interest due, convertible at holder’s option at $0.3235688 per TBT - DE share, interest rate 30%	$	10,000	$	10,000	$	10,000

Note payable to non-related party, unsecured, due 2/18/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 18%

750

Note payable to non-related party, unsecured, due 2/18/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 18%

6,875

Note payable to non-related party, unsecured, due 2/15/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 12%

2,500

Note payable to non-related party, unsecured, due 2/20/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 12%

3,750

Note payable to non-related party, unsecured, due 2/21/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 12%

2,625

Note payable to non-related party, unsecured, due 3/20/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 12%

5,433

Note payable to non-related party, unsecured, due 3/22/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 12%

3,203

TransBiotec, Inc.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note payable to non-related party, unsecured, due 1/05/13, annual interest due, convertible at holder’s option at 51% of market as defined, interest rate 8%, conversion limited to total beneficial ownership of 4.99%

10,500

Note payable to non-related party, unsecured, due 2/25/13, annual interest due, convertible at holder’s option at 51% of market as defined, interest rate 8%, conversion limited to total beneficial ownership of 4.99%

37,500

19,250

Note payable to related party, unsecured, $731,763, 5-years at 0% simple interest, due 7/1/2016, payment amounts vary each month, various late penalties.

726,763

Note payable to non-related party, unsecured, due 4/19/13, annual interest due, convertible at holder’s option at 51% of market as defined, interest rate 8%, conversion limited to total beneficial ownership of 4.99%

35,000

52,500

Note payable to non-related party, unsecured, due 08/29/2013, simple interest 8% convertible at holder’s option at $.249 per TBT-CA share.

15,000

Note payable to non-related party, unsecured, due 03/01/2013, simple interest 9%.

5,000

Note payable to non-related party, unsecured, due 01/31/2013, $12,000 in interest (2 months)

32,000

Note payable to non-related party, unsecured, due 12/13/2013, simple interest 7%.

5,342

Note payable to non-related party, unsecured, due 01/31/2013, simple interest 18%.

3,938

Note payable to non-related party, unsecured, due on demand, simple interest 7%, convertible at anytime into common stock at 65% of market closing price on previous day

55,000

Note payable to non-related party, unsecured, due 01/07/2014, simple interest 7%, default interest 10%, stock option

15,000

Note payable to non-related party, unsecured, due 01/15/2014, simple interest 7%, default interest 10%, stock option

5,000


Note payable to non-related party, unsecured, due 01/20/2014, simple interest 7%, default interest 10%, stock option			-				-			$	65,272

Note payable to non-related party, unsecured, due 03/28/2013, $13,000 in interest (1 month)

45,000

Note payable to non-related party, unsecured, due 01/23/2014, simple interest 9%,

50,000

Note payable to non-related party, unsecured, due 05/05/2014, simple interest 7%, default interest 10%, stock option

50,060

TransBiotec, Inc.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note payable to non-related party, unsecured, due 10/25/2013, simple interest 18%,

2,000

Note payable to non-related party, unsecured, due 07/29/2014, simple interest 7%, default interest 10%, stock option

1,900

Note payable to non-related party, unsecured, due 09/19/2014, simple interest 7%, default interest 10%, stock option

10,000

Note payable to non-related party, unsecured, due 09/19/2014, simple interest 7%, default interest 10%, stock option

65,000

Note payable to non-related party, unsecured, due 09/29/2014, simple interest 7%, default interest 10%, stock option

20,000

Note payable to non-related party, unsecured, due 12/27/2013, simple interest 9%,

15,000

Note payable to non-related party, unsecured, due 07/02/2014, simple interest 9%,

15,000

	$	826,523		$	979,939		$	1,350,921
Less current portion		(277,260	)		(616,051	)		(1,183,914	)

Long-term portion	$	549,263		$	363,888		$	167,007

Required principal payments from December 31, 2013 forward are as follows:

2013	$	689,801
2014	$	494,113
2015	$	123,709
2016	$	43,298
2017	$	-
	$	1,350,921

TransBiotec, Inc.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Interest expense under notes payable for the nine months ended September 30, 2013 and September 30, 2012 was $86,214 and $56,938, respectively.

During the nine months ended September 30, 2013 and September 30, 2012 the Company recognized a beneficial conversion feature expense on borrowing from convertible notes of $152,993 and $102,388, respectively. At September 30, 2013 the unamortized note discount from the beneficial conversion feature was $29,164.

In 2012 the Company borrowed $110,000 under convertible notes with a variable conversion price based on a percentage of market price. $27,000 of the notes were converted in 2012. The Company determined that these notes have an embedded derivative and are therefore accounted for at fair value. The Company recorded an expense of $448,137 in 2012 for fair value adjustments based on the Black-Scholes method using the following assumptions: risk free interest rate of 0.08%, dividend yield of 0%, expected life of 2-4 months, volatility of 172% - 197%. During the six months ended June 30, 2013 the Company borrowed $75,000 under a convertible note with a variable conversion price based on a percentage of market price. The note was not converted as of June 30, 2013. The Company determined that this note has an embedded derivative and are therefore accounted for at fair value. The Company recorded an expense of $389,297 during the six months ended June 30, 2013 for fair value adjustments based on the Black-Scholes method using the following assumptions: risk free interest rate of 0.08%, dividend yield of 0%, expected life of 2 – 4 months, volatility of 172% - 197%. The fair equity obligation liability under the notes at June 30, 2013 was $832,565.

	December 31,				Unaudited
	2011		2012		Sept. 30, 2013
Convertible debenture payable to unrelated party, unsecured, due 04/1/2009, convertible at holder's option at $.25 per share, interest rate 8% Default interest rate 12%	$	30,000	$	-	$	-

NOTE 5. INCOME TAXES

Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.

NOTE 6. STOCK OPTIONS AND SUBSCRIPTIONS PAYABLE

The Company accounts for employee and non-employee stock options under ASC 718, whereby option costs are recorded based on the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Unless otherwise provided for, the Company covers option exercises by issuing new shares.

The Company’s stock option activity is described below.

TransBiotec, Inc.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Non-employee stock options

At the beginning of 2011, the Company had 22,500 options outstanding for shares in Transbiotec – CA. During the year ended December 31, 2011 no options were exercised or expired, leaving a December 31, 2011 outstanding balance of 22,500 non-employee stock options, exercisable at prices from $0.10 - $0.15 per share with the option terms expiring from January 2012 through January 2015. All of these options are for the stock of TransBiotec - CA. During the year ended December 31, 2012 no options were exercised, and 20,000 options expired, leaving a December 31, 2012 outstanding balance of 2,500 non-employee stock options, exercisable at $0.10 per share with the option terms expiring in January 2015. All of these options are for the stock of TransBiotec - CA.

During 2012 the Company granted 29,678 stock options for shares in Transbiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rate of 0.8%, dividend yield of 0%, expected life of five years, volatility of 189%. No options were exercised or expired, leaving a December 31, 2012 outstanding balance of 29,678 options for Transbiotec – DE. The Company incurred and recorded compensation expense under these stock option grants of $4,042 in 2012.

During the nine months ended September 30, 2013 the Company granted 2,996,893 stock options for shares in Transbiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rate of 0.8%, dividend yield of 0%, expected life of five years, a volatility range of 185% - 190%. No options were exercised or expired, leaving a September 30, 2013 outstanding balance of 3,049,071 options for Transbiotec – DE. The Company incurred and recorded compensation expense under these stock option grants of $121,330 during the nine months ended September 30, 2013.

Employee stock options

The parent company had no outstanding employee stock options.

Stock subscriptions payable

At September 30, 2013 the Company had stock subscriptions payable of $26,000 for 80,696 common shares to be issued.

NOTE 7. GOING CONCERN

The Company has suffered recurring losses from operations and has a working capital deficit and stockholders' deficit, and in all likelihood will be required to make significant future expenditures in connection with continuing marketing efforts along with general administrative expenses. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

The Company may raise additional capital through the sale of its equity securities, through an offering of debt securities, or through borrowings from financial institutions or others. By doing so, the Company hopes to generate revenues from sales of its alcohol sensing and ignition lock systems. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern.

TransBiotec, Inc.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 8. OTHER MATTERS

In 2012 the Company filed an action in the Superior Court of California, Orange County against a shareholder group for business interference and breach of contract. The shareholder group had alleged various accusations of malfeasance toward the Company and filed an involuntary bankruptcy action against the Company in US Bankruptcy Court, Santa Ana Division. In January 2013 the parties reached a settlement whereby the Company agreed to pay various judgments held by the shareholder group of approximately $65,000 in exchange for the shareholder group surrendering its shares in the Company.

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Disclaimer Regarding Forward Looking Statements

Our Management’s Discussion and Analysis or Plan of Operations contains not only statements that are historical facts, but also statements that are forward-looking. Forward-looking statements are, by their very nature, uncertain and risky. These risks and uncertainties include international, national and local general economic and market conditions; demographic changes; our ability to sustain, manage, or forecast growth; our ability to successfully make and integrate acquisitions; raw material costs and availability; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to protect technology; and other risks that might be detailed from time to time in our filings with the Securities and Exchange Commission.

Although the forward-looking statements in this Quarterly Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by them. Consequently, and because forward-looking statements are inherently subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this report and in our other reports as we attempt to advise interested parties of the risks and factors that may affect our business, financial condition, and results of operations and prospects.

Overview

We are a development stage company that has developed an alcohol detection device called “SOBR”. The device is a patented device for use in detecting alcohol in a person’s system by testing the ethanol content in their perspiration. We plan to market the device to two primary business segments: (i) companies and institutions that employ or contract with vehicle drivers, where the system will be marketed as a preventative drunk driving detection system, with a possible ignition locking device, and (ii) companies and institutions that have an interest in monitoring their employees’ or contractors’ alcohol level due to their job responsibilities, such as surgeons prior to entering surgery, pilots prior to flying aircraft, and the military for personnel returning to a military base from off-base leave. Currently, we have several “prototype” units fully-developed that we believe are ready for use, but are also constantly looking for ways to improve the device and will develop it further if we find improvements to the device.

Regarding the use in vehicles, we believe SOBR offers a unique solution to the national drunk driving problem and are currently performing beta testing of SOBR for this use. Our objective is to grow our sales and manufacturing of SOBR by aggressively pursuing the original equipment market (“OEM”) once final beta testing is completed. We intend to seek an experienced OEM partner to introduce SOBR to the new automotive market. We believe that an increase in public awareness and consumer interest will generate a demand for alcohol sensing technology and we hope that auto manufactures will begin installing SOBR as a factory installed option. We will also market SOBR to international car manufacturers which may want to gain a market advantage over domestic auto manufacturers. We will seek to enter other markets as well, such as commercial trucking, as well as seek to have included in federal legislation a requirement that a alcohol sensing devices with ignition locking systems be retrofitted in all vehicles in the U.S.

Regarding the use in monitoring employees and contractors in certain industries, such as surgeons, pilots and the military, we are in the process of soliciting potential customers interested in purchasing either interlocking or portable devices in various industries.

Currently, we do not have the money or funding to achieve the above goals and based on our revenues, cash on hand and current monthly burn rate of approximately $25,000, we will need to continue borrowing from our shareholders and other related parties, and/or raise money from the sales of our securities, to fund operations.

Corporate Overview

We were formed in August 2007 to publish and distribute Image Magazine, a monthly guide and entertainment source for the Denver, Colorado area. We generated only limited revenue and essentially abandoned its business plan in January 2009. On September 19, 2011 we acquired approximately 52% of the outstanding shares of TBT from TBT's directors, in exchange for 12,416,462 shares of our common stock.

On January 31, 2012, we acquired approximately 45% of the remaining outstanding shares of TBT in exchange for 10,973,678 shares of our common stock.

Between the acquisitions in September 2011 and January 2012 we own approximately 97% of the outstanding shares of TBT.

As a result of the acquisition, TBT's business is our business, and, unless otherwise indicated, any references to we or us, include the business and operations of TBT.

TBT as the accounting acquirer in the transaction recorded the acquisition as the issuance of stock for our net monetary assets accompanied by a recapitalization. This accounting for the transaction was identical to that resulting from a reverse acquisition, except that no goodwill or other intangible assets were recorded.

We have developed and patented a high technology, state-of-the-art transdermal sensing system that detects blood alcohol levels through a person's skin.

The following discussion:

o	summarizes our plan of operation; and

o	analyzes our financial condition and the results of our operations for the three and nine months ended September 30, 2013.

This discussion and analysis should be read in conjunction with TBT's financial statements included as part of this Quarterly Report on Form 10-Q, as well as TBT’s financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2012.

Results of Operations for Three Months Ended September 30, 2013 Compared to Three Months Ended September 30, 2012

Summary of Results of Operations

	Three Months Ended September 30,						Period from July 19, 2004 (Inception) to September 30,
	2013			2012			2013
Revenue	$	-		$	-			-

Operating expenses:

General and administrative		117,832			138,199			13,068,319
Amortization and Depreciation		194			152			76,931
Total operating expenses		118,026			138,351			13,145,250


Operating loss		(118,026	)		(138,351	)		(13,145,250	)

Interest expense		(25,014	)		(20,704	)		(1,184,063	)
Interest expense – beneficial conversion feature		(19,501	)		(38,217	)		(335,057	)
Gain/(Loss) on fair value adjustment – derivatives		318,799			-			(518,635	)
Gain on sale of fixed asset		-			-			4,790
Gain on debt reversal		81,307			-			86,878
Stock option expense		(40,377	)		-			(121,330	)

Net income (loss)	$	197,806		$	(197,272	)		(15,118,407	)

Operating Loss; Net Income (Loss)

Our net income/(loss) changed by $395,078, from ($197,806) to $197,806, from the three months ended September 30, 2012 compared to September 30, 2013. Our operating loss decreased by $20,325, from ($138,351) to ($118,026) for the same period. The change in our net income/(loss) for the three months ended September 30, 2013, compared to the prior year period is primarily a result of the gain on fair value adjustment – derivatives as a result of the impact of our increased stock price on certain convertible instruments, as well as an increase in interest expense due to a beneficial conversion feature in certain of our convertible instruments. These changes are detailed below.

Revenue .

We have not had any revenues since our inception. Prior to September 2011 we were a company involved in publishing and distributing Image Magazine. Since September 2011, we have been involved in the development, testing and marketing SOBR, our unique alcohol sensor technology. Although we have not had any sales to date, we believe we are close to our first sales and revenue, possibly during our first quarter of 2014, but we must successfully raise money in order to execute on our business plan.

General and Administrative Expenses .

General and administrative expenses decreased by $20,367, from $138,199 for the three months ended September 30, 2012 to $117,832 for the three months ended September 30, 2013, which were fairly similar for the two periods.

Interest Expense .

Interest expense increased from $20,704 for the three months ended September 30, 2012 to $25,014 for the three months ended September 30, 2013. For both periods these amounts are largely due to the interest we own on outstanding debt.

Interest Expense – Beneficial Conversion Feature

In the three months ended September 30, 2013 our interest expenses includes a beneficial conversion feature of $19,501, compared to $38,217 for the three months ended September 30, 2012, both related to a convertible debenture.

Gain on Fair Value Adjustment - Derivatives

During the three months ended September 30, 2013, we had gain on fair value adjustment – derivatives of $318,799 primarily due to the impact of an increase in our stock price on certain convertible instruments we have outstanding. We did not have a corresponding gain or loss for the three months ended September 30, 2012.

Gain on Debt Reversal

During the three months ended September 30, 2013, we recorded a gain on debt reversal of $81,307 related to amounts that were owed to Asher Enterprises under certain promissory notes, which amounts were converted to common stock. We did not have a corresponding gain on debt reversal for the three months ended September 30, 2012.

Results of Operations for Nine Months Ended September 30, 2013 Compared to Nine Months Ended September 30, 2012

Summary of Results of Operations

	Nine months ended September 30,						Period from July 19, 2004 (Inception) to September 30,
	2013			2012			2013
Revenue	$	-		$	-		$	-

Operating expenses:

General and administrative		500,370			2,315,046			13,068,319
Amortization and Depreciation		582			303			76,931
Total operating expenses		500,952			2,315,349			13,145,250

Operating loss		(500,952	)		(2,315,349	)		(13,145,250	)

Interest expense		(91,071	)		(69,384	)		(1,184,063	)
Interest expense – beneficial conversion feature		(152,993	)		(102,388	)		(335,057	)
Loss on fair value adjustment – derivatives		(70,498	)		-			(518,635	)
Gain on sale of fixed asset		-			4,790			4,790
Gain on debt reversal		86,878			-			86,878
Stock option expense		(121,330	)		-			(121,330	)

Net loss	$	(844,163	)	$	(2,474,471	)	$	(15,118,407	)

Operating Loss; Net Loss.

Our net loss decreased by $1,630,308, from ($2,474,471) to ($844,163), for the nine months ended September 30, 2012 compared to September 30, 2013. Our operating loss decreased by $1,814,397, from ($2,315,349) to ($500,952) for the same period. The significant decrease in operating loss and net loss compared to the prior year period is primarily a result of the decrease in general and administrative expenses, offset partially in our net loss by a loss on fair value adjustment – derivatives as a result of the impact of our decreased stock price on certain convertible instruments, as well as an increase in interest expense due to a beneficial conversion feature in certain of our convertible instruments. These changes are detailed below.

Revenue .

General and Administrative Expenses .

General and administrative expenses decreased by $1,814,676, from $2,315,046 for the nine months ended September 30, 2012 to $500,370 for the nine months ended September 30, 2013, primarily due to the fact we compensated certain service providers and consultants with shares of our common stock in the nine months ended September 30, 2012 and did not do the same during the nine months ended September 30, 2013. When we compensate service providers and/or consultants with shares our common stock the fair market value of those shares appears as a general and administrative expense and can cause our expenses to appear much higher than they actually are in terms of cost to us for the services provided.

Interest Income/Expense; Net .

Interest expense, net increased from $69,384 for the nine months ended September 30, 2012 to $91,071 for the nine months ended September 30, 2013. For both periods these amounts are largely due to the interest we owe on outstanding debt.

Interest Expense – Beneficial Conversion Feature

In the nine months ended September 30, 2013 our interest expenses includes a beneficial conversion feature of $152,993, compared to $102,388 for the nine months ended September 30, 2012, both related to a convertible debenture.

Loss on Fair Value Adjustment - Derivatives

During the nine months ended September 30, 2013, we incurred loss on fair value adjustment – derivatives of ($70,498) primarily due to the impact of a decline in our stock price on certain convertible instruments we have outstanding. We did not have a corresponding loss for the nine months ended September 30, 2012.

Gain on Debt Reversal

During the nine months ended September 30, 2013, we recorded a gain on debt reversal of $86,878 related to amounts that were owed to Asher Enterprises under certain promissory notes, which amounts were converted to common stock. We did not have a corresponding gain on debt reversal for the nine months ended September 30, 2012.

Liquidity and Capital Resources for Nine Months Ended September 30, 2013 Compared to Nine Months Ended September 30, 2012

Introduction

During the nine months ended September 30, 2013 and 2012, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of September 30, 2013 was $837 and our monthly cash flow burn rate is approximately $20,000. As a result, we have significant short term cash needs. These needs are being satisfied through proceeds from the sales of our securities and loans from both related parties and third parties. We currently do not believe we will be able to satisfy our cash needs from our revenues for some time.

Our cash, current assets, total assets, current liabilities, and total liabilities as of September 30, 2013 and as of December 31, 2012, respectively, are as follows:

	September 30, 2013		December 31, 2012		Change

Cash	$	837	$	782	$	55
Total Current Assets		837		782		55
Total Assets		3,262		2,278		984
Total Current Liabilities		2,604,731		2,034,681		570,050
Total Liabilities	$	2,771,738	$	2,398,569	$	373,169

Our current assets increased by $55 as of September 30, 2013 as compared to December 31, 2012. The increase in our total assets between the two periods was attributed to a slight increase in our cash on hand as of September 30, 2013, since we did not have any current assets other than cash for the two periods presented.

Our current liabilities increased by $570,050, as of September 30, 2013 as compared to December 31, 2012. A large portion of this increase was due to an increase in our accounts payable of $160,613, an increase in our notes payable – current – related parties of $312,601 as a result of borrowing additional money from related parties, an increase in our notes payable – current of $255,262 as a result of borrowing additional money from non-related parties, offset by a decrease in other payables of $158,006.

In order to repay our obligations in full or in part when due, we will be required to raise significant capital from other sources. There is no assurance, however, that we will be successful in these efforts.

Cash Requirements

We had cash available as of September 30, 2013 of $837 and $782 on December 31, 2012. Based on our revenues, cash on hand and current monthly burn rate, around $20,000, we will need to continue borrowing from our shareholders and other related parties, and/or raise money from the sales of our securities, to fund operations.

Sources and Uses of Cash

Operations

We had net cash provided (used) by operating activities of ($340,384) for the nine months ended September 30, 2013, as compared to ($348,389) for the nine months ended September 30, 2012. For the period in 2013, the net cash used in operating activities consisted primarily of our net income (loss) of ($844,163) and gain on debt reversal of ($86,878), offset by compensatory equity issuances of $77,433, accrued payables of $276,650, fair value adjustments – equity obligations of $70,498, note payable beneficial conversion expense of $152,993, and original issue discount – interest expense of 12,510. For the period in 2012, the net cash provided by operating activities consisted primarily of our net income (loss) of ($348,389) and gain on sale of fixed asset of ($4,790), offset by compensatory equity issuances of $1,898,957, accrued payables of $89,941, and note payable beneficial conversion expense of $140,821.

Investments

We had net cash provided (used) by investing activities of ($511) for the nine months ended September 30, 2013 compared to $3,820 for the nine months ended September 30, 2012. In the nine months ended September 30, 2013 the net cash provided (used) by investing activities related fixed asset purchases of $511. In the nine months ended September 30, 2012 the net cash provided (used) by investing activities related to proceeds received from the sale of a fixed asset of $4,790, and fixed asset purchases of $970.

Financing

Our net cash provided (used) by financing activities for the nine months ended September 30, 2013 was $341,732, compared to $239,386 for the nine months ended September 30, 2012. For the period in 2013, our financing activities related to notes and loans payable – borrowings of $346,232 and equity issuances of $47,500, offset by notes and loans payables – payments of ($52,000). For the period in 2012, our financing activities consisted of equity issuances of $90,000 and notes and loans payable – borrowings of $149,386.

Off Balance Sheet Arrangements

We have no off balance sheet arrangements.

ITEM 3

Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we are not required to provide the information required by this Item.

ITEM 4

Controls and Procedures

(a) Evaluation of Disclosure Controls Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Disclosure and control procedures are also designed to ensure that such information is accumulated and communicated to management, including the chief executive officer and chief financial officer, to allow timely decisions regarding required disclosures.

As of September 30, 2013, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. In designing and evaluating the disclosure controls and procedures, management recognizes that there are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their desired control objectives. Additionally, in evaluating and implementing possible controls and procedures, management is required to apply its reasonable judgment. We also do not have an audit committee. Based on the evaluation described above, and as a result, in part, of not having an audit committee and having one individual serve as our chief executive officer and chief financial officer has concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were not effective to the same extent as reported in our Annual Report on Form 10-K for the year ended December 31, 2012.

As funds become available to us, we expect to implement additional measures to improve disclosure controls and procedures.

(b) Changes in Internal Controls over Financial Reporting

There was no change in our internal controls over financial reporting that occurred during the period covered by this report, which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

Appearing as an exhibit to this quarterly report on Form 10-Q are “Certifications” of our Chief Executive and Financial Officer. The Certifications are required pursuant to Sections 302 of the Sarbanes-Oxley Act of 2002 (the “Section 302 Certifications”). This section of the quarterly report on Form 10-Q contains information concerning the Controls Evaluation referred to in the Section 302 Certifications. This information should be read in conjunction with the Section 302 Certifications for a more complete understanding of the topics presented.

PART II – OTHER INFORMATION

ITEM 1

Legal Proceedings

On December 21, 2012, we were mail served with a legal action entitled, Involuntary Petition, Chapter 7, pursuant to which petitioning creditor Bill Bowman filed an involuntary bankruptcy proceeding with the stated purpose of putting TransBiotec, Inc., a California corporation and our wholly-owned subsidiary, into a bankruptcy (the “Involuntary Petition”). Subsequently we entered into a Settlement Agreement with Mr. Bowman (the “Bowman Settlement”) and on April 2, 2013 Mr. Bowman filed a Motion to Dismiss with the Court to have this matter dismissed with prejudice. The Court approved the Motion to Dismiss and issued an Order to Dismiss the legal action, effective July 29, 2013. On August 29, 2013, the parties to the Bowman Settlement amended the Settlement Agreement allowing us to make one final payment of $75,000 to Bowman as final payment under the Bowman Settlement. We made the payment on or about September 4, 2013, and we do not owe Mr. Bowman any further sums and lawsuits involving Mr. Bowman have been dismissed.

On December 6, 2006, Orange County Valet and Security Patrol, Inc. filed a lawsuit against us in Orange County California State Superior Court for Breach of Contract in the amount of $9,720.00. A default judgment was taken against us in this matter. However, the judgment had not been entered for a long period time, but we recently learned the Plaintiff’s have perfected the judgment against us, but we have not heard from the Plaintiffs for a long period time.

On May 11, 2012, we sued William Cooper, Travis Cooper and William Bowman, and KULA Management, Inc., an unknown entity in a case entitled, TransBiotec, Inc. v. William Cooper, Travis Cooper, William Bowman , Superior Court of California, County of Orange, Case No. 30-2012-00568440-CU-BC- CJC , for breach of contract, intentional interference, with contractual relations, intentional interference with prospective economic relations, defamation, and unfair business practices. According to the Complaint the lawsuit was based on false and misleading claims made by the Defendants, as well as tortious interference with our business and contacts. The Complaint sought unspecified damages to be determined by the Court or trier of fact. William Cooper, Travis Cooper and William Bowman all filed timely Answers. Kula Management, Inc. did not file an Answer and we received a default judgment against Kula Management, Inc. Travis Cooper and William Cooper filed cross-complaints alleging breach of contract. William Cooper’s cross-complaint was disallowed due to failure to file timely. As part of the Bowman Settlement mentioned above, this lawsuit was dismissed by all parties, effective March 22, 2013.

We currently have one outstanding judgment against us involving a past employee of the company. The matter is under the purview of the State of California, Franchise Tax Board, Industrial Health and Safety Collections. We currently owe approximately $28,277, plus accrued interest, to our ex-employee for unpaid wages under these Orders and are working to get this amount paid off.

On November 14, 2005, Fashion Furniture Rental, Inc. filed a lawsuit against TBT in the Orange County California State Superior Court for breach of contract. In 2012 Fashion Furniture Rental obtained a judgment against the Company in the approximate amount of $61,000. This judgment was subsequently assigned to Mr. Bowman, who asserted it in the aforementioned Involuntary Petition. This judgment has been partially satisfied in conjunction with the Bowman Settlement after paying $14,535.72 on the amount due. Per the terms of the Bowman Settlement, the remaining amount ($84,703.04 as of September 30, 2013) is to be fully satisfied by the end of this year. As part of the final settlement with Bowman per the August 29, 2013 amendment to the Bowman Settlement, the remaining amounts due hereunder have been satisfied.

On December 5, 2007, a judgment in favor of Vitaly Telishevsky in the amount of $29,791.43 was entered against TBT. This judgment was entered pursuant to an "Order, Decision or Award of the Labor Commissioner." The judgment was later assigned to Mr. Bowman, who asserted it in the Involuntary Petition. This judgment has been partially satisfied in conjunction with the Bowman Settlement after paying $14,089.87 on the amount due. Per the terms of the Bowman Settlement, the remaining amount ($31,144.22 as of September 30, 2013) it is to be fully satisfied by the end of this year. We are currently working on satisfying the remainder due under this judgment. As part of the final settlement with Bowman per the August 29, 2013 amendment to the Bowman Settlement, the remaining amounts due hereunder have been satisfied.

On September 30, 2006, a judgment in favor of Dai Vu in the amount of $22,065.44 was entered against TBT. This judgment was entered pursuant to an "Order, Decision or Award of the Labor Commissioner." The judgment was later assigned to Mr. Bowman, who asserted it in the Involuntary Petition. This judgment has been fully satisfied in conjunction with the Bowman Settlement.

In the ordinary course of business, we are from time to time involved in various pending or threatened legal actions. The litigation process is inherently uncertain and it is possible that the resolution of such matters might have a material adverse effect upon our financial condition and/or results of operations. However, in the opinion of our management, other than as set forth herein, matters currently pending or threatened against us are not expected to have a material adverse effect on our financial position or results of operations.

ITEM 1A

Risk Factors

As a smaller reporting company, we are not required to provide the information required by this Item.

ITEM 2

Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended September 30, 2013, we issued the following unregistered securities:

During the three months ended September 30, 2013, we issued an aggregate of 1,947,069 shares of our common stock, restricted in accordance with Rule 144, to Asher Enterprises, Inc., upon the conversion by Asher of $81,307 of debt we owe to them under a Convertible Promissory Note, currently in default. Based on the representations of the investor in the Convertible Promissory Note and the Notice of Conversion, the issuance of the shares was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933. The investor was accredited and sophisticated, familiar with our operations, and there was no solicitation.

During the three months ended September 30, 2013, we issued 150,000 shares of our common stock, restricted in accordance with Rule 144, to Scott Painter, one of our former officers and directors, pursuant to a Settlement Agreement we entered into with Mr. Painter on May 14, 2013. Based on Mr. Painter’s position as one of our former officers and directors the issuance of the shares was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933. The investor was accredited and sophisticated, familiar with our operations, and there was no solicitation.

ITEM 3

Defaults Upon Senior Securities

There have been no events which are required to be reported under this Item.

ITEM 4

Mine Safety Disclosures

There have been no events which are required to be reported under this Item.

ITEM 5

Other Information

There have been no events which are required to be reported under this Item.

ITEM 6

Exhibits

Item No.		Description

3.1 (1)		Articles of Incorporation of Imagine Media, Ltd.

3.2 (3)		Articles of Amendment to Articles of Incorporation to TransBiotec, Inc.

3.3 (1)		Bylaws of Imagine Media, Ltd.

10.1 (1)		Spin-of Trust Agreement by and between Gregory A. Bloom and Imagine Holding Corp. dated August 10, 2007

10.2 (1)		Form of Work For Hire Agreement

10.3 (1)		Assignment and Assumption Agreement by and between Imagine Holding Corp. and Imagine Media, Ltd. dated August 23, 2007

10.4 (2)		Investment Agreement by and between TransBiotec, Inc. and Kodiak Capital Group, LLC dated August 15, 2012

10.5 (3)		Amendment No. 1 to Investment Agreement by and between TransBiotec, Inc. and Kodiak Capital Group, LLC dated October 18, 2012

10.6 (2)		Registration Rights Agreement by and between TransBiotec, Inc. and Kodiak Capital Group, LLC dated August 15, 2012

10.7		Settlement Agreement by and between TransBiotec, Inc., et al and Bowman & Co., et al dated March 13, 2013

10.8		Settlement Agreement by and between TransBiotec, Inc., and Scott Painter dated May 14, 2013

10.9		Amendment No. 1 to Settlement Agreement by and between TransBiotec, Inc., et al and Bowman & Co., et al dated August 29, 2013

31.1		Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer (filed herewith).

31.2		Rule 13a-14(a)/15d-14(a) Certification of Chief Accounting Officer (filed herewith).

32.1		Section 1350 Certification of Chief Executive Officer (filed herewith).

32.2		Section 1350 Certification of Chief Accounting Officer (filed herewith).

101.INS **		XBRL Instance Document

101.SCH **		XBRL Taxonomy Extension Schema Document

101.CAL **		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF **		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB **		XBRL Taxonomy Extension Label Linkbase Document

101.PRE **		XBRL Taxonomy Extension Presentation Linkbase Document

** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

(1) Incorporated by reference from our Registration Statement on Form SB-2, filed with the Commission on January 31, 2008.

(2) Incorporated by reference from our Current Report on Form 8-K, filed with the Commission on September 11, 2012.

(3) Incorporated by reference from our Registration Statement on Form S-1, filed with the Commission on November 6, 2012.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TransBiotec, Inc.

Dated: November 14, 2013	By:	/s/ Charles Bennington
		Charles Bennington
		President

TABLE OF CONTENTS

Part I Financial Information Item 1 Financial Statements Note 1. Organization, Operations and Summary Of Significant Accounting Policies Note 1. Organization, Operations and Summary Of Significant Accounting Policies (cont D)Note 2. Related Party Transactions Note 3. Fixed Assets Note 4. Notes Payable Note 5. Income Taxes Note 6. Stock Options and Subscriptions Payable Note 7. Going Concern Note 8. Other Matters Item 2 Management S Discussion and Analysis Of Financial Condition and Results Of Operations Item 3 Quantitative and Qualitative Disclosures About Market Risk Item 4 Controls and Procedures Part II Other Information Item 1 Legal Proceedings Item 1A Risk Factors Item 2 Unregistered Sales Of Equity Securities and Use Of Proceeds Item 3 Defaults Upon Senior Securities Item 4 Mine Safety Disclosures Item 5 Other Information Item 6 Exhibits Item No. Description

SOBR 10-Q Quarter ended Sept. 30, 2013